We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Argent Biopharma Limited | LSE:RGT | London | Ordinary Share | AU0000326647 | ORD NPV (DI) |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 6.50 | 5.00 | 8.00 | 6.50 | 6.50 | 6.50 | 1,516 | 00:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
0 | 0 | N/A | 0 |
RNS Number:6723Q ReGen Therapeutics PLC 08 October 2003 ReGen Therapeutics Plc 8 October 2003 SUBSTANTIAL SHAREHOLDING ReGen Therapeutics Plc (the "Company") announces that on 8 October 2003 it received notification from Mr P. Garrod that he is beneficially interested in 24,000,000 ordinary shares of the Company representing 10.69% of the current issued share capital of the Company. For further information, please contact: Andrew Marshall Marshall Robinson Roe Tel. 020 7960 6007 This information is provided by RNS The company news service from the London Stock Exchange END HOLEALEPESLDFFE
1 Year Argent Biopharma Chart |
1 Month Argent Biopharma Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions